Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly

Annals of Clinical Biochemistry

Volumn 38, Issue 4, 2001, Pages 297-303

  Peacey, S R ^a   Shalet, S M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; DISEASE ACTIVITY; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REVIEW; TRANSSPHENOIDAL HYPOPHYSECTOMY;

ACROMEGALY; BIOLOGICAL MARKERS; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 0034944024     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563011900678     Document Type: Review

References (64)

1. Epidemiology of acromegaly in the Newcastle region
2. Epidemiology and long-term survival in acromegaly
3. Acromegaly
4. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat
5. Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanaesthetized sheep
6. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40)
7. Physiological role of somatostatin on growth hormone regulation in humans
8. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses
9. The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man
10. Increased growth hormone pulse frequency in acromegaly
11. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy
12. Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumours
13. Growth hormone secretion in recently operated acromegalic patients
14. Growth hormone pulsatility in active and cured acromegalic subjects
15. Characterization of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy
16. Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release
17. Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery
18. Insulin-like growth factors I and II; peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations
19. Insulin-like growth factors
20. Plasma insulin-like growth factor l/somatomedin C in acromegaly: Correlation with the degree of growth hormone hypersecretion
21. Relationships between insulin-like growth factor-I levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly
22. Surgical management of acromegaly
23. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly
24. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
25. Low-dose pituitary radiation for acromegaly
26. Hypopituitarism following external radiotherapy for pituitary tumours in adults
27. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
28. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six month report on an Italian multicenter study. Italian multicenter slow release lanreotide study group
29. Sandostatin LAR in acromegalic patients: Long term treatment
30. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
31. Substantial tumour shrinkage after primary octreotide therapy for acromegaly: An open prospective study with centralised imaging analysis
32. Octreotide as primary therapy for acromegaly
33. Treatment of acromegaly with dopamine agonists
34. Cabergoline treatment of acromegaly: A preliminary dose finding study
35. Cabergoline in the treatment of acromegaly: A study of 64 patients
36. Cabergoline in acromegaly: A renewed role for dopamine agonist treatment?
37. Mortality in acromegaly
38. An audit of outcome of treatment in acromegaly
39. Determinants of clinical outcome and survival in acromegaly
40. Mortality and cancer incidence in acromegaly: A retrospective cohort study
41. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
42. The relationship between 24-hour growth hormone (GH) secretion and insulin-like growth factor-I in patients with successfully treated acromegaly: Impact of surgery or radiotherapy
43. Normal growth hormone response to 75 g oral glucose tolerance test measured by immunoradiometric assay
44. Criteria for cure of acromegaly: A consensus statement
45. IGFBP3 is a poor parameter in the assessment of clinical activity in acromegaly
46. A comparison of different methods for diagnosing acromegaly
47. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion
48. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly
49. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly
50. The assay of urinary growth hormone in normal and acromegalic adults
51. Evaluation of acromegaly by measurement of 24 hourly urinary growth hormone excretion
52. Quantification of urinary growth hormone (GH) excretion by centrifugal ultrafiltration and radioimmunoassay: Appraisal of the relationship between 24 h urinary GH and mean serum GH levels in normal and abnormal states of GH secretion
53. Overnight urinary growth hormone measurement in the diagnosis of acromegaly
54. Urinary growth hormone excretion in acromegaly: Diagnostic value in mild disease activity
55. Hypothalamic dysfunction in 'cured' acromegaly is treatment modality dependent
56. Growth hormone pulsatility in acromegaly following radiotherapy
57. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
58. Human aging and the GHIGF-1 axis
59. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study
60. Chronic sex steroid exposure increases mean plasma growth hormone concentration and pulse amplitude in men with isolated hypogonadotrophic hypogonadism
61. Mechanisms of thyroid hormone action on the insulin-like growth factor system: All thyroid hormone effects are not growth hormone mediated
62. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients
63. The diagnosis of growth hormone deficiency (GHD) in adults
64. New approach to the diagnosis of growth hormone deficiency in adults